leisure time -WSS

leisure time

author：fashion 2025-09-05 13:47:07 - browse：48545

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： The health care issue Democrats can’t solve: hospital reform

focus

WSS

JPM pitch from hospitals? Revenue streams outside of patient care

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Gene therapy denied for Afghan refugee whose father aided U.S.

Hospital chaplains balance Covid safety with patients’ spiritual needs

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

What is microchimerism and how does it affect maternal health?

entertainment

leisure time

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT Virtual Event: JPM Recap, Live!

In Memoriam: Notable people who died in 2023

Allen Institute goes after foundational questions, CEO Costa says

Hepatitis C has a cure — but many Americans still lack access to it

Bill would allow buprenorphine prescription for addiction via telehealth

Trump demands the U.S. pay no more for drugs than other countries … again

Life sciences investors close nearly $6 billion in new funds

Hollywood unions extend contract negotiations for actors

Merck to acquire Harpoon Therapeutics for $680 million

hotspot

Profiling embryos to choose those with higher IQs is almost a reality

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Profiling embryos to choose those with higher IQs is almost a reality

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Fauci's latest grilling in Congress: 9 hours, behind closed doors

entertainment

focus

Wikipedia

focus